CA2327708A1 - Antioxidant stabilizer system for pharmaceutical formulations - Google Patents

Antioxidant stabilizer system for pharmaceutical formulations Download PDF

Info

Publication number
CA2327708A1
CA2327708A1 CA002327708A CA2327708A CA2327708A1 CA 2327708 A1 CA2327708 A1 CA 2327708A1 CA 002327708 A CA002327708 A CA 002327708A CA 2327708 A CA2327708 A CA 2327708A CA 2327708 A1 CA2327708 A1 CA 2327708A1
Authority
CA
Canada
Prior art keywords
acid
carboxylic acid
hydrogen
alkyl
organic carboxylic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002327708A
Other languages
English (en)
French (fr)
Inventor
Philip C. Lang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roberts Laboratories Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2327708A1 publication Critical patent/CA2327708A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002327708A 1998-04-08 1998-11-16 Antioxidant stabilizer system for pharmaceutical formulations Abandoned CA2327708A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/057,260 US5962488A (en) 1998-04-08 1998-04-08 Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives
US09/057,260 1998-04-08
PCT/US1998/024471 WO1999052529A1 (en) 1998-04-08 1998-11-16 Antioxidant stabilizer system for pharmaceutical formulations

Publications (1)

Publication Number Publication Date
CA2327708A1 true CA2327708A1 (en) 1999-10-21

Family

ID=22009506

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002327708A Abandoned CA2327708A1 (en) 1998-04-08 1998-11-16 Antioxidant stabilizer system for pharmaceutical formulations

Country Status (7)

Country Link
US (2) US5962488A (enExample)
EP (1) EP1067927B1 (enExample)
JP (1) JP2003522724A (enExample)
AT (1) ATE318598T1 (enExample)
CA (1) CA2327708A1 (enExample)
DE (1) DE69833684T2 (enExample)
WO (1) WO1999052529A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962488A (en) * 1998-04-08 1999-10-05 Roberts Laboratories, Inc. Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives
US6632452B1 (en) * 1999-01-21 2003-10-14 Shionogi & Co., Ltd. Medicinal compositions retarded in the discoloration of phenolic hydroxyl compounds
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20090186083A1 (en) * 2005-10-19 2009-07-23 Dainippon Sumitomo Pharma Co., Ltd Method for stabilization of isoxazole compound
DE102007025275A1 (de) * 2007-05-31 2008-12-04 Qiagen Gmbh Butendisäure oder deren Derivate zur Behandlung einer biologischen Probe
EP2249811A1 (en) 2008-01-25 2010-11-17 Grünenthal GmbH Pharmaceutical dosage form
KR101690094B1 (ko) 2008-05-09 2016-12-27 그뤼넨탈 게엠베하 분무 응결 단계의 사용하에 중간 분말 제형 및 최종 고체 제형을 제조하는 방법
US9186411B2 (en) * 2008-07-28 2015-11-17 Takeda Pharmaceutical Company Limited Pharmaceutical composition
SI2456424T1 (sl) * 2009-07-22 2013-10-30 Gruenenthal Gmbh Oksidacijsko stabilizirana odmerna oblika, varna pred zlorabo
AR077493A1 (es) 2009-07-22 2011-08-31 Gruenenthal Gmbh Composicion farmaceutica extruida en caliente con liberacion controlada. procedimiento de preparacion
MX2013002377A (es) 2010-09-02 2013-04-29 Gruenenthal Gmbh Forma de dosificacion resistente a manipulacion que comprende una sal inorganica.
PL2611425T3 (pl) 2010-09-02 2014-09-30 Gruenenthal Gmbh Odporna na ingerencję postać dawki zawierająca polimer anionowy
JP2014524925A (ja) 2011-07-29 2014-09-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時薬剤放出を提供するタンパーレジスタント錠剤
EP2736497B1 (en) 2011-07-29 2017-08-23 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
AR090695A1 (es) 2012-04-18 2014-12-03 Gruenenthal Gmbh Forma de dosificacion farmaceutica resistente a la adulteracion y resistente a la liberacion inmediata de la dosis
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
MX371432B (es) 2013-05-29 2020-01-30 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido que contiene una o mas particulas.
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
EA032465B1 (ru) 2013-07-12 2019-05-31 Грюненталь Гмбх Защищенная от применения не по назначению пероральная фармацевтическая лекарственная форма, содержащая этиленвинилацетатный полимер, и способ ее изготовления
BR112016010482B1 (pt) 2013-11-26 2022-11-16 Grünenthal GmbH Preparação de uma composição farmacêutica em pó por meio de criomoagem
MX2016014738A (es) 2014-05-12 2017-03-06 Gruenenthal Gmbh Formulacion en capsula de liberacion inmediata resistente a alteraciones que comprende tapentadol.
MX2016015417A (es) 2014-05-26 2017-02-22 Gruenenthal Gmbh Multiparticulas protegidas contra vertido de dosis etanolico.
EA035434B1 (ru) 2015-04-24 2020-06-15 Грюненталь Гмбх Защищенная от применения не по назначению лекарственная форма с немедленным высвобождением и устойчивостью к экстракции растворителями
CN107750159B (zh) * 2015-06-23 2021-10-29 英特维特国际股份有限公司 用于消毒的饮用水的含有维生素的异噁唑啉溶液
WO2017042325A1 (en) 2015-09-10 2017-03-16 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
MX2023003783A (es) * 2020-10-01 2023-04-26 Imago Biosciences Inc Formulaciones farmaceuticas para tratar enfermedades mediadas por kdm1a.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB679192A (en) * 1948-07-09 1952-09-17 Eastman Kodak Co Method of stabilizing fats and fatty oils against oxidation
GB682205A (en) * 1949-03-16 1952-11-05 Eastman Kodak Co Improvements in and relating to anti-oxidants for oils and fats
US4091091A (en) * 1973-11-08 1978-05-23 Eli Lilly And Company Stabilized nitroglycerin tablets
JPS5299242A (en) * 1976-02-12 1977-08-19 Tanabe Seiyaku Co Antiioxidant
JPS62153385A (ja) * 1985-12-27 1987-07-08 Riken Vitamin Co Ltd 酸化防止剤
US4837031A (en) * 1987-09-17 1989-06-06 Mallinckrodt, Inc. Compositions containing ibuprofen
CA1335106C (en) * 1989-02-27 1995-04-04 John Mehnert Schaus Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes
US5420151A (en) * 1989-12-22 1995-05-30 Aktiebolaget Astra Chroman derivatives
DK0471515T3 (da) * 1990-08-15 1997-07-21 Lilly Co Eli Ringsubstituerede 2-amino-1,2,3,4-tetrahydronphtalener, 3-aminochromaner og 3-aminothiochromaner
US5077069A (en) * 1991-01-07 1991-12-31 Kabi Pharmacia Ab Composition of natural antioxidants for the stabilization of polyunsaturated oils
CA2077628C (en) * 1991-01-07 2000-06-06 Stephen S. Chang Composition of natural antioxidants for the stabilization of polyunsaturated oils
JPH05339154A (ja) * 1992-06-03 1993-12-21 Sagami Chem Res Center 肝機能改善剤
US5434174A (en) * 1992-07-17 1995-07-18 Eli Lilly And Company Isoxazole derivatives for the treatment of irritable bowel syndrome
JPH0717855A (ja) * 1992-09-02 1995-01-20 Maruha Corp 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品
JPH09509138A (ja) * 1993-10-25 1997-09-16 メレルファーマスーティカルズ インコーポレイテッド ターフェナジン及びイブプロフェンの安定な製剤組成物
JPH09194362A (ja) * 1996-01-19 1997-07-29 Bizen Kasei Kk ドコサヘキサエン酸及びエイコサペンタエン酸含有リン脂質を含む組成物
JP3941073B2 (ja) * 1996-03-01 2007-07-04 日本油脂株式会社 油脂組成物及びそれを含む食品
US5962488A (en) * 1998-04-08 1999-10-05 Roberts Laboratories, Inc. Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives

Also Published As

Publication number Publication date
EP1067927A1 (en) 2001-01-17
DE69833684T2 (de) 2006-11-16
ATE318598T1 (de) 2006-03-15
JP2003522724A (ja) 2003-07-29
US6479529B1 (en) 2002-11-12
EP1067927B1 (en) 2006-03-01
US5962488A (en) 1999-10-05
EP1067927A4 (en) 2003-04-23
WO1999052529A1 (en) 1999-10-21
DE69833684D1 (de) 2006-04-27

Similar Documents

Publication Publication Date Title
CA2327708A1 (en) Antioxidant stabilizer system for pharmaceutical formulations
CA1297024C (en) Drug compositions stabilized against oxidation
JP2619904B2 (ja) 安定化された組成物
EP0840603B1 (en) Pharmaceutical composition of l-dopa ethyl ester
KR960000431B1 (ko) 안정한된 약제 조성물
US20080075773A1 (en) New Oral Formulation
EA000976B1 (ru) Композиция для снятия боли и способ снятия боли
RU2284819C2 (ru) Стабильная пероральная твердая композиция лекарственного препарата
HUT71235A (en) Pharmaceutical compositions against endometriosis containing 2-phenyl-3-aroil-benzotiophene derivatives and process for their preparation
AP324A (en) Medicaments for treating inflammatory conditions or for analgiesia.
WO2000028993A1 (en) Serotonin ligands as pro-erectile compounds
CA2432644A1 (en) Pharmaceutical composition comprising aspirintm and cs-747
EA008108B1 (ru) Комбинация нспвлс и ингибитора pde-4
BRPI0609952A2 (pt) métodos para modular a função da bexiga
HUT71477A (en) Pharmaceutical compositions for increasing libido in post-menopausal women containing 2-phenyl-3-aroil-benzothiophene derivatives and process for their preparation
HUT71329A (en) Pharmaceutical compositions for inhibiting cns problems in post-menopausal women containing 2-phenyl-3-aroyl-benzothiophene-derivatives and process for their preparation
US5002946A (en) Phenylethanolamine analog active compounds for the treatment of gastrointestinal diseases
JP2575569B2 (ja) 薬物従属症及び禁断症状の治療に関するグリシン／ｎｍｄａレセプターリガンドの用法
US4465692A (en) Selective D-2 dopamine receptor agonist
US20030212050A1 (en) Prophylactic treatment of migraine
HU225779B1 (en) Pharmaceutical composition containing paracetamol and drotaverine and process for producing it
BG61242B2 (bg) Твърд фармацевтичен състав за орална употреба на база дапипразол
US5525605A (en) Remedy for inflammatory intestinal diseases
US5270341A (en) Method of treatment or prophylaxis of depression and stress
WO2011126327A2 (en) Pharmaceutical composition with controlled-release properties comprising mosapride or levodropropizine, and preparing method thereof

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued